Aberrations in fibroblast growth factor receptor (FGFR) signaling are an emerging focus for targeted therapy across multiple types of cancer, particularly urothelial carcinoma, gastric cancer, and intrahepatic cholangiocarcinoma.
Original Article: FGFR Alterations Emerge as Enticing Target in Multiple Tumor Types